First Commonwealth Financial Corp Gilead Sciences, Inc. Transaction History

First Commonwealth Financial Corp

$400 Million
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $6,943 - $8,467	-97 Reduced 3.32%	2,826 $207,000
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $14,727 - $16,701	-201 Reduced 6.43%	2,923 $236,000
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $73 - $80	-1 Reduced 0.03%	3,124 $234,000
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $29,567 - $33,726	389 Added 14.22%	3,125 $240,000
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $170,507 - $244,789	2,736 New	2,736 $234,000
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $214,999 - $269,416	-3,712 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $7,136 - $8,100	-110 Reduced 2.88%	3,712 $269,000
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $27,076 - $29,212	-400 Reduced 9.47%	3,822 $267,000
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $13,646 - $14,910	-215 Reduced 4.85%	4,222 $291,000
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $2,400 - $2,738	-40 Reduced 0.89%	4,437 $286,000
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $14,407 - $18,114	-232 Reduced 4.93%	4,477 $283,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $12,297 - $14,280	-170 Reduced 3.48%	4,709 $363,000
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $8,705 - $11,150	-139 Reduced 2.77%	4,879 $365,000
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $18,486 - $20,334	-300 Reduced 5.64%	5,018 $326,000
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $36,880 - $40,710	-590 Reduced 9.99%	5,318 $337,000
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $43,309 - $48,566	-700 Reduced 10.59%	5,908 $399,000
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $37,518 - $42,030	-600 Reduced 8.32%	6,608 $430,000
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $7,083 - $9,243	-117 Reduced 1.6%	7,208 $451,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $165,369 - $183,094	-2,320 Reduced 24.05%	7,325 $566,000
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $1,232 - $1,437	-19 Reduced 0.2%	9,645 $683,000
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $48,147 - $58,696	-661 Reduced 6.4%	9,664 $728,000
Q4 2017 Feb 15, 2018	SELL	$71.15 - $83.52 $145,644 - $170,965	-2,047 Reduced 16.55%	10,325 $740,000
Q3 2017 Nov 13, 2017	SELL	$72.11 - $85.47 $127,418 - $151,025	-1,767 Reduced 12.5%	12,372 $1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	14,139	14,139 $1 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Commonwealth Financial Corp , based on Form 13F filings with the SEC.

News

Stay updated on First Commonwealth Financial Corp with notifications on news.

Account